Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in CLDI held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 879K | $210K | β | 48.833% | 0.01% |
| 2 | SABBY MANAGEMENT, LLC | 435K | $104K | β | 24.161% | 1.82% |
| 3 | Warberg Asset Management LLC | 250K | $59K | β | 13.889% | 0.02% |
| 4 | HighTower Advisors, LLC | 84K | $20K | 0.0% | 4.640% | 0.00% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 63K | $15K | +50.3% | 3.501% | 0.00% |
| 6 | RS CRUM INC. | 40K | $10K | +98.7% | 2.236% | 0.00% |
| 7 | SRS Capital Advisors, Inc. | 37K | $9K | β | 2.075% | 0.00% |
| 8 | JANE STREET GROUP, LLC | 35K | $8K | +202.9% | 1.933% | 0.00% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 26K | $6K | β | 1.417% | 0.00% |
| 10 | Belpointe Asset Management LLC | 20K | $5K | -0.3% | 1.107% | 0.00% |
| 11 | NORTHERN TRUST CORP | 18K | $4K | 0.0% | 0.987% | 0.00% |
| 12 | Farther Finance Advisors, LLC | 10K | $2K | 0.0% | 0.556% | 0.00% |
| 13 | MORGAN STANLEY | 9K | $2K | +545.3% | 0.526% | 0.00% |
| 14 | VANGUARD FIDUCIARY TRUST CO | 9K | $2K | β | 0.512% | 0.00% |
| 15 | ADVISOR GROUP HOLDINGS, INC. | 2K | $503 | 0.0% | 0.117% | 0.00% |
| 16 | Tower Research Capital LLC (TRC) | 1K | $333 | -49.7% | 0.078% | 0.00% |
| 17 | Apollo Management Holdings, L.P. | 1K | $249 | 0.0% | 0.058% | 0.00% |
| 18 | Finepoint Capital LP | 1K | $249 | 0.0% | 0.058% | 0.00% |
| 19 | JPMORGAN CHASE & CO | 1K | $248 | β | 0.058% | 0.00% |
| 20 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 1K | $248 | 0.0% | 0.058% | 0.00% |
| 21 | FMR LLC | 255 | $61 | -98.8% | 0.014% | 0.00% |
| 22 | SBI Securities Co., Ltd. | 115 | $27 | +150.0% | 0.006% | 0.00% |
| 23 | Tradewinds Capital Management, LLC | 101 | $25 | 0.0% | 0.006% | 0.00% |
| 24 | Reyes Financial Architecture, Inc. | 100 | $24 | 0.0% | 0.006% | 0.00% |
| 25 | Virtu Financial LLC | 76K | $18 | +256.7% | 4.209% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in CLDI β a direct measure of their conviction.
Filings activity in CLDI during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 29 | +16% | 171.62% | +49.45 pp | $0M | +40% |
| Q4 2025 | 25 | +14% | 122.17% | 10.02 pp | $0M | 7.6% |
| Q3 2025 | 22 | 39% | 132.19% | 67.80 pp | $0M | 45% |
| Q2 2025 | 36 | 2.7% | 199.99% | +0.00 pp | $1M | 79% |
| Q1 2025 | 37 | +8.8% | 199.99% | +0.00 pp | $3M | +164% |
| Q4 2024 | 34 | +62% | 199.99% | +64.13 pp | $1M | +218% |
| Q3 2024 | 21 | 36% | 135.86% | 50.41 pp | $0M | 27% |
| Q2 2024 | 33 | β | 186.27% | β | $0M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying CLDI stock.
Based on Q1 2026 13F filings, institutional ownership of Calidi Biotherapeutics, Inc. stands at 171.6%, held across 29 reporting institutions.
ARMISTICE CAPITAL, LLC is the largest reported institutional holder of CLDI, with approximately 879,000 shares worth $0.00B as of Q1 2026.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of CLDI, including JANE STREET GROUP, LLC.
Our composite Smart Money Score for CLDI is 64 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
8 institutions opened new positions in CLDI during Q1 2026, while 4 fully exited. 2 added to existing positions and 19 trimmed.
CLDI institutional ownership rose by 49.45 percentage points quarter-over-quarter, with a net change of +4 holders.
The top 10 institutions account for 97.1% of all reported 13F value in CLDI, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Calidi Biotherapeutics, Inc. (CLDI) Institutional Ownership